- ASCO May 29- June 2, 2026: Genentech will present data on nine medicines across 15+ indications, including lidERA giredestrant results submitted to the FDA for early ER+, HER2- breast cancer.
- The FDA has accepted a New Drug Application for giredestrant based on evERA data in patients previously treated with CDK4/6 inhibitors.
- PersevERA did not meet its primary endpoint but showed a numerical improvement in progression-free survival with first-line giredestrant plus palbociclib.
- Divarasib (KRAS G12C inhibitor) plus pembrolizumab first-line results from Krascendo-170 informed the Phase III Krascendo-2, and divarasib is being evaluated in three pivotal Phase III studies.
ASCO presentations
Genentech will present data at ASCO (May 29–June 2, 2026) on nine approved and investigational medicines across more than 15 indications, with emphasis on breast, hematologic and lung cancers.
Giredestrant program
Giredestrant, an oral SERD for ER+, HER2– disease, features three Phase III programs: lidERA showed a 30% reduction in invasive disease recurrence or death (Dec 2025) and submitted data will evaluate consistency across pre‑ and post‑menopausal patients; evERA analyses of giredestrant+everolimus in post‑CDK4/6 inhibitor patients supported FDA acceptance of an NDA; persevERA did not meet its primary endpoint but showed a numerical PFS improvement for first‑line giredestrant+palbociclib versus letrozole+palbociclib.
HER2 and breast‑cancer analyses
Preliminary Phase Ic expansion results for ZN‑A‑1041, a blood–brain barrier‑permeable HER2 TKI, will report safety/efficacy in combination with trastuzumab deruxtecan or pertuzumab‑trastuzumab; additional breast presentations include INAVO120 analyses of inavolisib by lobular histology and a US real‑world comparison of adjuvant ADC eligibility (KATHERINE vs DESTINY‑Breast05 populations).
Other clinical programs
Divarasib (KRAS G12C inhibitor) plus pembrolizumab results from Krascendo‑170 informed the Phase III Krascendo‑2 and divarasib is in three pivotal Phase III studies; SUNMO will present updated Phase III data comparing mosunetuzumab+polatuzumab vedotin versus R‑GemOx in relapsed/refractory DLBCL (including 2L subgroup); additional hematology and thoracic entries include long‑term glofitamab data in MCL, Polivy biomarker analyses and multiple Tecentriq studies in lung, hepatocellular and colorectal/bladder settings.
